Dexcom Launches Stelo: First OTC Glucose Monitor for Non-Insulin Users

In a groundbreaking development, Dexcom has launched Stelo, its first over-the-counter continuous glucose monitor (CGM), designed specifically for individuals with Type 2 diabetes who do not require insulin. Priced at $89 per month, this innovation is poised to significantly impact diabetes management and broaden Dexcom’s market reach.

Dexcom’s entry into the over-the-counter (OTC) market marks a pivotal expansion of its product offerings. Known primarily for their prescription CGM devices, Dexcom’s new product, Stelo, represents a shift towards making diabetes management more accessible. The device is designed to offer non-insulin users—or even those without diabetes—the ability to monitor glucose levels similarly to those who rely on insulin, thus broadening its user base and potentially increasing market penetration.

The launch comes at a crucial time. Dexcom recently faced a sales forecast shortfall for 2024, lowering its revenue expectations to between $4 billion and $4.05 billion from an initial range of $4.2 billion to $4.35 billion.